Integra LifeSciences Shares Drop to Record Low on Unexpected Loss, Boston Facility Audit Findings
By Sabela Ojea
Shares of Integra LifeSciences dropped to a new 52-week low after the company reported an unexpected first-quarter loss and said an external audit detected more findings than anticipated at its Boston facility.
The stock was down 17% to $23.94 on Monday, on track for the lowest close in about 10 years. Shares have plunged 53% over the past two months.
The medical technology company posted a net loss of $3.3 million, or 4 cents a share, compared with a profit of $24.2 million, or 29 cents a share, for the same period a year earlier. Analysts polled by FactSet had forecast earnings per share of 12 cents.
Revenue fell 3.1% to $368.9 million, ahead of the $362 million forecast by analysts.
The company now forecasts full-year revenue of $1.67 billion to $1.69 billion from $1.6 billion to $1.62 billion previously, but it will no longer include $10 million due to the relaunch of SurgiMend and PriMatrix beginning in the second half.
The SurgiMend and PriMatrix's products guidance comes as Integra LifeSciences evaluates the timeline to address the findings from a third-party audit at its Boston facility.
In July, the Food and Drug Administration warned the company about having a number of devices adulterated at its Boston facility that didn't follow the good manufacturing practice requirements of the quality system regulation.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
May 06, 2024 12:47 ET (16:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing